Silver Book Fact

Stroke risk reduction from thrombin inhibitor in AFib patients

A recently approved direct thrombin inhibitor was found to reduce the risk of stroke/peripheral embolic events in atrial fibrillation patients by 34%, and the risk of hemorrhagic stroke by 74%—compared with warfarin.

Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson, BI, OE Dahl, N Rosencher, AA Kurth, CN van Dijk, SP Frostick, MH Prins, R Nettiarachchi, S Hantel, J Schnee, and HR Buller; for the RE-NOVATE Study Group
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Atrial fibrillation ablation prevents recurrence of AFib
    Atrial fibrillation ablation, which involves using a catheter inserted into the heart to destroy electrical conduction tissue in or near the atria, prevents the recurrence of atrial fibrillation in up…  
  • Cost-savings associated with optimal anticoagulation in AFib patients
    If half of all atrial fibrillation patients receiving suboptimal or no anticoagulation instead received optimal anticoagulation, 28,000 strokes could be prevented each year at a savings of around $2.5 billion in direct…  
  • Decrease in AFib hospitalization rates
    The use of practice guidelines in atrial fibrillation patients saw a decrease in rate of hospitalization from 74%to 38%.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • AFib practice guidelines reduce direct health care costs
    The use of practice guidelines in atrial fibrillation (AF) patients significantly decreased hospitalization and resource utilization—with an average decrease in 30-day total direct health care costs of around $1,400 per patient.